SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001516551-24-000052
Filing Date
2024-04-03
Accepted
2024-04-03 17:07:54
Documents
14
Period of Report
2024-04-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K skye-20240403.htm   iXBRL 8-K 31020
2 EX-99.1 a991_unauditedproformabala.htm EX-99.1 52659
  Complete submission text file 0001516551-24-000052.txt   203470

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20240403.xsd EX-101.SCH 1923
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20240403_lab.xml EX-101.LAB 20073
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20240403_pre.xml EX-101.PRE 11528
17 EXTRACTED XBRL INSTANCE DOCUMENT skye-20240403_htm.xml XML 2537
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

IRS No.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-55136 | Film No.: 24819896
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)